PARP1 and neoplasm: Furthermore, co-targeting DNA damage repair pathways through poly (ADP-ribose) polymerase (PARP) inhibition in combination with ICIs offers a dual mechanism: destabilizing the tumor genome while concurrently enhancing immune visibility (120, 121).